Abstract：
Meningococcal disease is highly transmissible, life-threatening and leaves significant sequelae in survivors. Every year, India, which has a plethora of risk factors for meningococcal disease, reports around 3000 endemic cases. However, the overall disease burden and serogroup distribution are unknown, creating a setting of general disease negligence and unawareness. Vaccination with quadrivalent meningococcal conjugate vaccine A, C, W, and Y is only recommended for high-risk children, and there is no overall guidance for meningococcal serogroup B (MenB) vaccination. MenB vaccines, which recently have been licensed in many countries but not in India, have significantly aided the fight against meningococcal disease. However, these MenB vaccines are not available in India. An Expert Consensus Group meeting was held with leading meningococcal disease experts to better understand the current disease epidemiology, particularly serogroup B, the prevalence gaps, and feasible ways to bridge them. The proceedings are presented in this paper.
摘要：
脑膜炎球菌病是高度传染性的，危及生命，并在幸存者中留下重大后遗症。每年,印度,脑膜炎球菌疾病的危险因素过多，报告了大约3000例地方性病例。然而,总体疾病负担和血清群分布未知，创造了一个普遍的疾病疏忽和无意识的环境。接种四价脑膜炎球菌结合疫苗A，C,W,Y只推荐给高危儿童,并且对于脑膜炎球菌血清群B（MenB）疫苗接种没有总体指导。MenB疫苗，最近在许多国家获得许可，但在印度没有，大大有助于抗击脑膜炎球菌病。然而,这些MenB疫苗在印度不可用。与主要脑膜炎球菌疾病专家举行了专家共识小组会议，以更好地了解当前的疾病流行病学，特别是血清群B，患病率差距，以及弥合它们的可行方法。本文介绍了诉讼程序。
